Interferon-β inhibits glioma angiogenesis through downregulation of vascular endothelial growth factor and upregulation of interferon inducible protein 10

Takano,Shingo; Ishikawa,Eiichi; Matsuda,Masahide; Yamamoto,Tetsuya; Matsumura,Akira

doi:10.3892/ijo.2014.2620

Interferon-β inhibits glioma angiogenesis through downregulation of vascular endothelial growth factor and upregulation of interferon inducible protein 10

Authors:
- Shingo Takano
- Eiichi Ishikawa
- Masahide Matsuda
- Tetsuya Yamamoto
- Akira Matsumura
View Affiliations

Affiliations: Department of Neurosurgery, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki 305-8575, Japan
Published online on: August 25, 2014 https://doi.org/10.3892/ijo.2014.2620
Pages: 1837-1846
Copyright: © Takano et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Interferon-β (IFN-β) has been used clinically for malignant glioma growth inhibition. Recently IFN-β is re-evaluated for its sensitization mechanism to the chemotherapeutic agent temozolomide, because angiogenesis is essential for malignant glioma growth. In this study, we investigated new mechanisms of inhibition of glioma angiogenesis by IFN-β. Three malignant glioma cell lines, U87, TK2 and Becker, were used for in vitro study. The effect of IFN-β for these cell lines were evaluated by means of proliferation (MTT assay), conditioned medium induced HUVEC migration, VEGF and interferon inducible protein 10 (IP10, angiogenesis inhibitor) expression by RT-PCR and western blot analysis. SCID mouse U87 subcutaneous model and U87 implant cranial window model were used for in vivo study. The effect of IFN-β with the models was evaluated by means of tumor growth, tumor tissue expression for VEGF and IP10, tumor tissue CD31 positive vessel densities, apoptosis and tumor microcirculation (blood velocity, interaction between leukocytes and endothelial cells). In vitro, IFN-β upregulated IP10 expression and downregulated VEGF expression time- (4-48 h) and dose- (10-5,000 U/ml) dependently. At the same dose, glioma cell-induced HUVEC migration was inhibited, but cell proliferation was not affected. IFN-β local and systemic injection at 105 U and at 5x105 U/day, for 15 days inhibited U87 subcutaneous growth significantly. In the tumor tissues, VEGF expression and vessel densities were downregulated, but IP10 expression and apoptosis index upregulated. In addition, IFN-β local injection increased collagen fiber deposition in the tumor tissues. IFN-β 5x105 U/day, s.c. injection for 7 days reversed the decreased leukocyte adhesion to endothelial cells, but did not affect blood velocity and vessel images. One of the important roles of IFN-β for malignant glioma growth inhibition was anti-angiogenesis by directly inhibiting angiogenesis through downregulation of VEGF and upregulation of IP-10 and indirectly changing the tumor microcirculation and regulating the interstitial pressure.

View Figures

View References

1	Fine HA, Wen PY, Robertson M, O’Neill A, Kowal J, Loeffler JS and Black PML: A phase I trial of a new recombinant human β-interferon (BG9015) for the treatment of patients with recurrent gliomas. Clin Cancer Res. 3:381–387. 1997.
2	Natsume A, Ishii D, Wakabayashi T, Tsuno T, Hatano H, Mizuno M and Yoshida J: IFN-beta down-regulates the expression of DNA repair gene MGMT and sensitizes resistant glioma cells to temozolomide. Cancer Res. 65:7573–7579. 2005.PubMed/NCBI
3	Yoshino A, Ogino A, Yachi K, Ohta T, Fukushima T, Watanabe T, Katayama Y, Okamoto Y, Naruse N and Sano E: Effect of IFN-beta on human glioma cell lines with temozolomide resistance. Int J Oncol. 35:139–148. 2009. View Article : Google Scholar : PubMed/NCBI
4	Wakabayashi T, Kayama T, Nishikawa R, Takahashi H, Hashimoto N, Takahashi J, Aoki T, Sugiyama K, Ogura M, Natsume A and Yoshida J: A multicenter phase I trial of combination therapy with interferon-beta and temozolomide for high-grade gliomas (INTEGRA study): the final report. J Neurooncol. 104:573–577. 2011. View Article : Google Scholar : PubMed/NCBI
5	Colman H, Berkey BA, Maor MH, Groves MD, Schultz CJ, Vermeulen S, Nelson DF, Mehta MP and Yung WK; Radiation Therapy Oncology Group. Phase II Radiation Therapy Oncology Group trial of conventional radiation therapy followed by treatment with recombinant interferon-beta for supratentorial glioblastoma: results of RTOG 9710. Int J Radiat Oncol Biol Phys. 66:818–824. 2006. View Article : Google Scholar
6	Motomura K, Natsume A, Kishida Y, Higashi H, Kondo Y, Nakasu Y, Abe T, Namb H, Wakai K and Wakabayashi T: Benefits of interferon-beta and temozolomide combination therapy for newly diagnosed primary glioblastoma with the unmethylated MGMT promoter: a multicenter study. Cancer. 117:1721–1730. 2011. View Article : Google Scholar : PubMed/NCBI
7	Brem S, Cotran R and Folkman J: Tumor angiogenesis: a quantitative method for histologic grading. J Natl Cancer Inst. 48:347–356. 1972.PubMed/NCBI
8	Norden AD, Drappatz J and Wen PY: Novel anti-angiogenic therapies for malignant gliomas. Lancet Neurol. 7:1152–1160. 2008. View Article : Google Scholar : PubMed/NCBI
9	Nagane M, Nishikawa R, Narita Y, Kobayashi H, Takano S, Shinoura N, Aoki T, Sugiyama K, Kuratsu J, Muragaki Y, Sawamura Y and Matsutani M: Phase II study of single-agent bevacizumab in Japanese patients with recurrent malignant glioma. Jpn J Clin Oncol. 42:887–895. 2012. View Article : Google Scholar : PubMed/NCBI
10	Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, Carpentier AF, Hoang-Xuan K, Kavan P, Cernea D, Brandes AA, Hilton M, Abrey L and Cloughesy T: Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med. 370:709–722. 2014. View Article : Google Scholar : PubMed/NCBI
11	Singh RK, Gutman M, Bucana CD, Sanchez R, Llansa N and Fidler IJ: Interferons α and β down-regulate the expression of basic fibroblast growth factor in human carcinomas. Proc Natl Acad Sci USA. 92:4562–4566. 1995.
12	Dinney CPN, Bieleberg DR, Perrotte P, Reich R, Eve BY, Bucana CD and Fidler IJ: Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-α administration. Cancer Res. 58:808–814. 1998.PubMed/NCBI
13	Gohji K, Fidler IJ, Tsan R, Radinsky R, von Eschenbach AC, Tsuruo T and Nakajima M: Human recombinant interferon-beta and -gamma decrease gelatinase production and invasion by human KG-2 renal-carcinoma cells. Int J Cancer. 58:380–384. 1994. View Article : Google Scholar : PubMed/NCBI
14	Takano S, Gately S, Neville ME, Herblin WF, Gross JL, Engelhard H, Perricone M, Eidsvoog K and Brem S: Suramin, an anticancer and angiosuppressive agent, inhibits endothelial cell binding of basic fibroblast growth factor, migration, proliferation, and induction of urokinase-type plasminogen activator. Cancer Res. 54:2654–2660. 1994.
15	Takano S, Tsuboi K, Matsumura A, Tomono Y, Mistui Y and Nose T: Expression of the angiogenic factor thymidine phosphorylase in human astrocytic tumors. J Cancer Res Clin Oncol. 126:145–152. 2000. View Article : Google Scholar : PubMed/NCBI
16	Boorsma DM, de Haan P, Willemze R and Stoof TJ: Human growth factor (huGRO), interleukin-8 (IL-8) and interferon-gamma-inducible protein (gamma-IP-10) gene expression in cultured normal human keratinocytes. Arch Dermatol Res. 286:471–475. 1994. View Article : Google Scholar
17	Takano S, Yoshii Y, Kondo S, Maruno T, Shirai S and Nose T: Concentration of vascular endothelial growth factor in the serum and tumor tissue of brain tumor patients. Cancer Res. 56:2185–2190. 1996.PubMed/NCBI
18	Suzuki T, Yanagi K, Ookawa K, Hatakeyama K and Ohshima N: Flow visualization of microcirculation in solid tumor tissues: intravital microscopic observation of blood circulation by use of a confocal laser microscope. Front Med Biol Eng. 7:253–263. 1996.
19	Foltz RM, McLendon RE, Friedman HS, Dodge RK, Bigner DD and Dewhirst MW: A pial window model for the intracranial study of human glioma microvascular function. Neurosurgery. 36:976–984. 1995. View Article : Google Scholar : PubMed/NCBI
20	Ezekowitz RAB, Mulliken JB and Folkman J: Interferon alfa 2a therapy for life-threatening hemangiomas in infancy. N Engl J Med. 324:1456–1463. 1992. View Article : Google Scholar
21	Orchard PJ, Smith CM, Woods WG, Day DL, Dehner LP and Shapiro R: Treatment of haemangio endotheliomas with alpha interferon. Lancet. 2:565–567. 1989. View Article : Google Scholar : PubMed/NCBI
22	Kirn DH and Kramer A: Long-term function from disease progression with interferon alfa therapy in two patients with malignant hemangiopericytoma. J Natl Cancer Inst. 88:764–765. 1996. View Article : Google Scholar : PubMed/NCBI
23	Real FX, Qettgen HF and Kroun SE: Kaposi’s sarcoma and the acquired immunodeficiency syndrome: treatment with high and low doses of recombinant leukocyte α interferon. J Clin Oncol. 4:544–551. 1986.
24	Stout AJ, Gresser I and Thompson WD: Inhibition of wound healing in mice by local interferon-β injection. Int J Exp Pathol. 74:79–85. 1993.
25	Oliveira IC, Sciavolino PJ, Lee TH and Vilcek J: Downregulation of interleukin 8 gene expression in human fibroblasts: unique mechanism of transcriptional inhibition by interferon. Proc Natl Acad Sci USA. 89:9049–9053. 1992. View Article : Google Scholar : PubMed/NCBI
26	Boethius J, Blomgren H, Collins VP, Greitz T and Strander H: The effect of human interferon-α administration to patients with glioblastoma multiforme. Acta Neurochir. 68:239–251. 1983.
27	Rozera C, Carlei D, Lollini PL, De Giovanni C, Musiani P, Di Carlo E, Belardelli F and Ferrantini M: Interferon (IFN)-β gene transfer into TS/A adenocarcinoma cells and comparison with IFN-α. Am J Pathol. 154:1211–1222. 1999.
28	Hong YK, Chung DS, Joe YA, Yang YJ, Kim KM, Park YS, Yung WKA and Kang JK: Efficient inhibition of in vivo human malignant glioma growth and angiogenesis by interferon-β treatment at early stage of tumor development. Clin Cancer Res. 6:3354–3360. 2000.PubMed/NCBI
29	Zheng H, Qian J, Carbone CJ, Leu NA, Baker DP and Fuchs SY: Vascular endothelial growth factor-induced elimination of the type 1 interferon receptor is required for efficient angiogenesis. Blood. 118:4003–4006. 2011. View Article : Google Scholar : PubMed/NCBI
30	Xiao HB, Zhou WY, Chen XF, Mei J, Lv ZW, Ding FB, Li GQ, Zhong H and Bao CR: Interferon-β efficiently inhibited endothelial progenitor cell-induced tumor angiogenesis. Gene Ther. 19:1030–1034. 2012.
31	Björndahl M, Cao R, Eriksson A and Cao Y: Blockage of VEGF-induced angiogenesis by preventing VEGF secretion. Circ Res. 94:1443–1450. 2004.PubMed/NCBI
32	Von Marschall A, Scholz A, Cramer T, Schafer G, Schirner M, Oberg K, Wiedenmann B, Hocker M and Rosewicz S: Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis. J Natl Cancer Inst. 95:421–437. 2003.PubMed/NCBI
33	Bedogni B, O’Neill MS, Welford SM, Bouley DM, Giaccia AJ, Denko NC and Powell MB: Topical treatment with inhibitors of the phosphatidylinositol 3′-kinase/Akt and Raf/mitogen-activated protein kinase kinase/extracellular signal-regulated kinase pathways reduces melanoma development in severe combined immunodeficient mice. Cancer Res. 64:2552–2560. 2004.
34	Raig ET, Jones NB, Varker KA, Benniger K, Go MR, Biber JL, Lesinski GB and Carson WE III: VEGF secretion is inhibited by interferon-alpha in several melanoma cell lines. J Interferon Cytokine Res. 28:553–561. 2008. View Article : Google Scholar : PubMed/NCBI
35	Yoshino A, Tashiro S, Ogino A, Yachi K, Ohta T, Fukushima T, Watanabe T, Katayama Y, Okamoto Y, Sano E and Tsumoto K: Gene expression profiles predicting the response to IFN-β and a combination of temozolomide and IFN-β in malignant gliomas. Int J Oncol. 39:529–542. 2011.
36	Keane MP, Arenberg DA, Moore BB, Addison CL and Strieter RM: CXC chemokines and angiogenesis/angiostasis. Proc Assoc Am Physicians. 110:288–296. 1998.PubMed/NCBI
37	Arenberg DA, Kunkel SL, Polverini PJ, Morris SB, Burdick MD, Glass MC, Taub DT, Iamettoni MD, Whyte RI and Strieter RM: Interferon-γ-inducible protein 10 (IP-10) is an angiostatic factor that inhibits human non-small cell lung cancer (NSCLC) tumorigenesis and spontaneous metastases. J Exp Med. 184:981–982. 1996.
38	Sato E, Fujimoto J and Tamaya T: Expression of interferon-gamma-inducible protein 10 related to angiogenesis in uterine endometrial cancers. Oncology. 73:246–251. 2007. View Article : Google Scholar : PubMed/NCBI
39	Liu M, Guo S and Stiles JK: The emerging role of CXCL10 in cancer (Review). Oncol Lett. 2:583–589. 2011.PubMed/NCBI
40	Yuan F, Salehi HA, Boucher Y, Vasthrae US, Tuma RF and Jain RK: Vascular permeability and microcirculation of gliomas and mammary carcinomas transplanted in rat and mouse cranial windows. Cancer Res. 54:4564–4568. 1994.PubMed/NCBI
41	Fatterpekar GM, Galheigo D, Narayana A, Johnson G and Knopp E: Treatment-related change versus tumor recurrence in high-grade gliomas: a diagnostic conundrum - use of dynamic susceptibility contrast-enhanced (DSC) perfusion MRI. AJR Am J Roentgenol. 198:19–26. 2012. View Article : Google Scholar
42	Emblem KE, Mouridsen K, Bjornerud A, Farrar CT, Jennings D, Borra RJ, Wen PY, Ivy P, Batchelor TT, Rosen BR, Jain RK and Sorensen AG: Vessel architectural imaging identifies cancer patient responders to anti-angiogenic therapy. Nat Med. 19:1178–1183. 2013. View Article : Google Scholar : PubMed/NCBI
43	Lou J, Gasche Y, Zheng L, Giroud C, Morel P, Clements J, Ythier A and Grau GE: Interferon-β inhibits activated leukocyte migration through human brain microvascular endothelial cell monolayer. Lab Invest. 79:1015–1025. 1999.
44	Kallmann B, Hummel V, Lindenlaub T, Ruprecht K, Toyka KV and Rieckmann P: Cytokine-induced modulation of cellular adhesion to human cerebral endothelial cells is mediated by soluble vascular cell adhesion molecule-1. Brain. 123:687–697. 2000. View Article : Google Scholar
45	Cindrova-Davies T, Sanders DA, Burton GJ and Charnock-Jones DS: Soluble FLT1 sensitizes endothelial cells to inflammatory cytokines by antagonizing VEGF receptor-mediated signalling. Cardiovasc Res. 89:671–679. 2011. View Article : Google Scholar : PubMed/NCBI
46	Goel S, Wong AH and Jain RK: Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease. Cold Spring Harb Perspect Med. 2:a0064862012. View Article : Google Scholar
47	Boucher E, Unemori B, Seed B and Jain RK: Relaxin increases the transport of large molecules in high collagen content tumors. Proc Am Assoc Cancer Res. 41:abs 642000.